Non-invasive optical spectroscopy
for improving the diagnosis of cancer

 

Luminostix commercialises Differential Pathlength Spectroscopy (DPS), a patented optical technology for quantitative measurements in optically diffuse media. Currently the main focus of Luminostix is the field of non invasive diagnosis of superficial cancer.

Currently, Luminostix is developing its first medical product.

Founded in 2006, Luminostix is a spin-off company from the Center for Optical Diagnosis and Therapy at the Erasmus Medical Center in Rotterdam.  

 

 

 

 

 

Company profile